undamentalytics Newsletter
Sign in

Heron Therapeutics, Inc. revenue

Heron Therapeutics, Inc.'s revenue was $155m in fiscal 2025, up 7.4% on the year before. Since fiscal 2016 ($1.3m) it has grown at a compound 70.4% a year. Over the last twelve months it was $151m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue131771468986108127144155151
Growth on the year before—+>999%+151.8%+88.4%−39.3%−2.6%+24.7%+18.0%+13.6%+7.4%—
Gross profit126508452405362106114106
Gross margin97.3%85.1%64.5%57.8%59.2%46.7%49.0%48.8%73.2%73.3%70.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
CINVANTI $96.8M 62.5% ▼ 3.3%
ZYNRELEF $38.1M 24.6% ▲ 49.0%
Aponvie $11.6M 7.5% ▲ 156.1%
SUSTOL $8.5M 5.5% ▼ 39.9%

From Heron Therapeutics, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Heron Therapeutics, Inc. $151m 1.0% 8.6%
Natural Alternatives International Inc $143m 9.7% -2.6%
Zevra Therapeutics, Inc. $136m 119.4% 101.9%
Amarin Corp plc\uk $176m -22.3% -18.3%
Niagen Bioscience, Inc. $129m 11.0% 16.8%
Cronos Group Inc. $179m 37.5% 30.3%

Compare with peers

Head to head: HRTX vs NAIIHRTX vs ZVRAAMRN vs HRTXHRTX vs NAGE

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Heron Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Heron Therapeutics, Inc.